Health

Veeva Gives Away Its AI Agents and Bills the Seat Migration

Barron's calls Veeva the plumbing of AI medicine and analyst coverage pitches 30% upside on a stock already up 27.87% this year. But Veeva's own releases show the flagship agent ships free and the marquee win had no disclosed value; the billable business is a CRM migration with a 2029 deadline.

Vincent JiangVincent Jiangthree-minute read
Share
A white pill under a laboratory light during pharmaceutical research
1 / 6Slide 1 of 6
Drug research in a pharmaceutical laboratory: Veeva's software sits underneath clinical trials and the industry's commercial data.

The plumbing call on a stock already up 28%

Barron's ended September with a stock pick titled "AI Will Revolutionize Medicine. This Company Provides the Plumbing" 1. The bull math sits elsewhere: analyst coverage on 1 October framed VEEV−1.74% — VEEV, down 1.74 percent today, trading near $285, as offering up to 30% upside over the next 12 months 11. The tape already moved. The stock closed 30 September at $285.45, up 2.47% on the day and 27.87% for the year, against an average target of $297.30 from 29 analysts 3. Wells Fargo's−2.46% — Wells Fargo, down 2.46 percent today Stan Berenshteyn carries Overweight at $330 311, and Asian trading coverage tied the move to the week's AI announcements 2.

Targets sit above a stock that already ran 28% this year

$0$100$200$300$400Close, 30 SepAverage target (29 analysts)Wells Fargo target$330
Data
Veeva share price and targets
Close, 30 Sep$285.45
Average target (29 analysts)$297.3
Wells Fargo target$330
Share price at the 30 September close and 12-month price targets, in US dollars. Sources: MarketScreener / S&P Capital IQ; CoinCentral analyst coverage.3,11

The flagship agent has no price on it

The re-rating rides on announcements with no revenue line. Study Builder Agent, unveiled 24 September, configures clinical data capture and quality systems straight from a study protocol in as little as one day. It requires no additional license: it ships inside Veeva EDC to early adopters in December 4.

Delivered as a Claude Cowork plugin, the agent's availability follows Anthropic's$350B — Anthropic, private, latest valuation $350B supported regions: the US, Europe, Japan and India. Mainland China, where Anthropic restricts its models, is out; Veeva Clinical Data CTO Drew Garty says study configuration there is not typically done by local teams anyway 5. The engine is rented from a company whose IPO prospectus points to a valuation above $2 trillion 6.

The week's other headline has no number either

Servier's OpenData standardization across more than 80 countries went out as a paid release with no contract value 7. Veeva's own promotion leans on the claim that the industry "fails to scale 89% of AI initiatives due to data challenges" 7. A foundation-governed French drugmaker adopting the data layer is a real win; it is just not yet a number.

What Veeva bills is the migration underneath

Subscriptions are 84% of sales 3. The billable machine is Vault CRM: more than 190 live customers and commitments from 14 of the top 20 biopharmas, including Amgen, Biogen, Eli Lilly−1.62% — Eli Lilly, down 1.62 percent today and Regeneron 8, up from 125 live in March 9.

That same month, Veeva pulled legacy CRM's end-of-support forward from September 2030 to December 2029 9, turning the installed base into a scheduled migration. Revenue does the quiet work: $927.96M in the quarter ended 31 July, up 17.6% year over year, the eighth straight quarterly rise on file 10.

Veeva's revenue has risen in each of the last eight reported quarters

$600M$700M$800M$900M$1,000MQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26$927.96MMarch 2026: Veeva AI available,125 live on Vault CRM
Data
Quarterly revenue
Q3 '24$699.21M
Q4 '24$720.89M
Q1 '25$759.04M
Q2 '25$789.08M
Q3 '25$811.24M
Q4 '25$835.95M
Q1 '26$882.95M
Q2 '26$927.96M
Quarterly revenue in US$ millions, as reported in SEC filings; labels are calendar quarters. Sources: Sharadar quarterly fundamentals from Veeva Systems filings, retrieved 1 October 2026; Veeva press release of 3 March 2026 for the March annotation.10,9

December decides the agent story

The bull case is not nothing: full-year guidance was raised toward $3.7 billion, a third upward revision this year, and management targets a $6 billion run rate by 2030 11. But the agents drawing the headlines are, in effect, retention spend, given away to defend the seats they run on. The rule the re-rating has to pass: the price stands on the seats that must move before December 2029, not on agents that ship free in December. Veeva is giving away the robots and charging for the moving vans.

Get Health by email, free

AI in medicine, pharma and biotech. In our daily email, every weekday.

Loading WFC

Reader comments

0 comments

    More in Health

    All in this topic →

    Health

    Molina Healthcare jumps 8% on a CMS work-rule delay; director Steven Orlando sold 702 shares at $227.33

    A CMS work-rule delay bought Molina's Medicaid book time, not margin, and insiders including director Steven Orlando sold into the strength. New buyers are paying roughly 24 times a 2027 framework that is not yet guidance and must still be earned in February.

    Health

    OpenAI prices healthcare back-office work at 8.5 cents a task, undercutting Ambience Healthcare

    OpenAI's new healthcare agents run prior-authorization work at 8.5 cents a task, and Menlo Ventures says the scribe market's new dollars are going to Microsoft and Epic. Ambience's $37,500-per-doctor receipt is now the only thing it sells that the model layer does not.

    Health

    Apple's 200,000-person health AI study runs on OpenEvidence with no disclosed price

    The 200,000-person study hands a $15 billion, ad-funded startup its first consumer channel, with no fee, equity or contract disclosed, and the closest public test of whether that free AI model is eating paid clinical reference lands in Wolters Kluwer's February results.

    Health

    Globus Medical director Tobin sold his entire stake for $3.1 million five days after a guidance cut

    James Tobin's November 10 sale left him with zero shares and zero options in Globus Medical, with no trading plan, five days after the company cut its 2026 revenue outlook by up to $130 million. The board's answer was a $500 million buyback increase.

    Health

    Molina Healthcare's CFO lays out a path to $9.50 EPS in 2027, on $4 of fixes not yet earned

    Molina's finance chief added $4 of "embedded earnings" to a $5.25 floor for 2027, assuming no recovery at all in Medicaid margins. Guidance, and the test of each dollar, arrives in February.

    Health

    Hims & Hers grew revenue 49% to $890 million, lost $33 million, and cut its 2026 profit outlook a third time

    Revenue grew 49% and the quarter still lost money, because selling Lilly's and Novo's branded weight-loss drugs books the full price without keeping it. Hims shareholders are paying for the pivot; Lilly gains a channel it barely needs.

    Subscribe to TheInference for free